"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 3 | 4 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 7 | 7 |
| 2003 | 2 | 2 | 4 |
| 2004 | 6 | 3 | 9 |
| 2005 | 2 | 5 | 7 |
| 2006 | 3 | 2 | 5 |
| 2007 | 5 | 2 | 7 |
| 2008 | 3 | 3 | 6 |
| 2009 | 8 | 3 | 11 |
| 2010 | 14 | 5 | 19 |
| 2011 | 12 | 3 | 15 |
| 2012 | 10 | 2 | 12 |
| 2013 | 9 | 5 | 14 |
| 2014 | 11 | 3 | 14 |
| 2015 | 8 | 3 | 11 |
| 2016 | 10 | 8 | 18 |
| 2017 | 10 | 10 | 20 |
| 2018 | 5 | 8 | 13 |
| 2019 | 8 | 10 | 18 |
| 2020 | 10 | 8 | 18 |
| 2021 | 6 | 13 | 19 |
| 2022 | 1 | 15 | 16 |
| 2023 | 2 | 10 | 12 |
| 2024 | 12 | 13 | 25 |
| 2025 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Differential Treatment Effects on ?-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025 Apr 01; 48(4):623-631.
-
Group-based trajectory modeling to identify longitudinal patterns and predictors of adherence among older adults on concomitant triple therapy (oral antidiabetic, renin-angiotensin-system antagonists, statins). J Manag Care Spec Pharm. 2025 Apr; 31(4):396-405.
-
Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care. 2025 Feb 01; 48(2):177-181.
-
Real-World Insights Into Hypoglycemia Risk While Driving in Teens and Young Adults With Type 1 Diabetes. Pediatr Diabetes. 2025; 2025:5053872.
-
Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy. Int Ophthalmol Clin. 2025 Jan 01; 65(1):23-26.
-
Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial. Diabetologia. 2025 Mar; 68(3):676-687.
-
International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies - Insulin Delivery. Horm Res Paediatr. 2024; 97(6):636-662.
-
Real-world treatment patterns in drug na?ve type 2 diabetes population: Initial combination therapy vs. sequential step-therapy. J Am Pharm Assoc (2003). 2025 Jan-Feb; 65(1):102295.
-
Noninsulin Diabetes Medications in Hospitalized Children and Adolescents. Crit Care Nurs Clin North Am. 2025 Mar; 37(1):19-33.
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.